

Resource Summary Report

Generated by [RRID](#) on Aug 12, 2026

Brilliant Violet 421(TM) anti-human CD25

RRID:AB_2562164

Type: Antibody

Proper Citation

BioLegend Cat# 356114, RRID:AB_2562164

Antibody Information

URL: http://antibodyregistry.org/AB_2562164

Proper Citation: BioLegend Cat# 356114, RRID:AB_2562164

Target Antigen: CD25

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human CD25

Description: This monoclonal targets CD25

Target Organism: human

Clone ID: Clone M-A251

Antibody ID: AB_2562164

Vendor: BioLegend

Catalog Number: 356114

Alternative Catalog Numbers: 356113

Record Creation Time: 20250819T232928+0000

Record Last Update: 20250820T052951+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD25.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD25.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Govindarajan M, et al. (2026) Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. Cell reports. Medicine, 7(2), 102578.

Sobu R, et al. (2026) IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model. iScience, 29(7), 116386.

Shang X, et al. (2026) Dual PD-1/IL-2R γ targeting restores CD8⁺ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. Cell reports. Medicine, 7(3), 102633.

Stockmann AP, et al. (2025) DF6215, an α -optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. Cell reports. Medicine, 102518.

Farhat AM, et al. (2021) Modeling cell-specific dynamics and regulation of the common gamma chain cytokines. Cell reports, 35(4), 109044.